Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Starting soon · Not applicable
Conditions studied: Cirrhosis
In brief
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \>9.
Key facts
- Study ID
- NCT07652203
- Run by
- General Hospital of Shenyang Military Region
- People needed
- 466
- Starts
- 2026-06-01
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients' age ≥18 years;
- patients with a definitive diagnosis of liver cirrhosis;
- patients with a MELD score of >9;
- patients with a history of decompensation or those who are experiencing their first decompensation, such as ascites, variceal bleeding, or hepatic encephalopathy (HE);
- patients' informed consents.
You may not qualify if…
- patients without a definite indication for NSBBs;
- patients with an absolute contraindication of NSBBs (severe bronchospasm, asthma, severe psychosis, high-degree atrioventricular block, etc.);
- patients with hypersensitivity to NSBBs;
- patients who had been treated with NSBBs before 2 weeks of enrollment;
- patients with occlusive portal vein thrombosis;
- patients who had undergone liver transplantation;
- patients who had undergone transjugular intrahepatic portosystemic shunt (TIPS);
- patients with a definitive diagnosis of hepatocellular carcinoma;
- patients with an estimated life time of <12 months due to the presence of any comorbidities;
- patients who are currently pregnant or breast-feeding.
Where it is running
- Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area) — Shenyang, Liaoning, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.